Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease
Authors' conclusion
CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.
Study context
- Population
- Individuals aged 40 to 70 years with established atherosclerotic cardiovascular disease (ASCVD) and whole-exome sequences, UK Biobank
- Participants
- 13,129 individuals
- Exposure
- Clonal hematopoiesis of indeterminate potential (CHIP) vs no CHIP
- CHIPn = 665
- Outcome
- Composite of:
- ASCVD events
- All-cause mortality
- Follow-up
- Median 10.8 years
Methodological detailsUK Biobank, multivariable-adjusted Cox regression
- UK Biobank
- Multivariable-adjusted Cox regression
Main finding
As reported in the abstract
Each group vs no CHIPAdjusted hazard ratio (95% CI)P value
CHIPany CHIP
1.23(1.10–1.38)
P < 0.001Large CHIPlarge CHIP
1.34(1.17–1.53)
P < 0.001Observational data: associations, not effects.
Further findings
Primary outcome by driver gene (large clones)
| HR (95% CI) | P value | ||
|---|---|---|---|
| Large TET2 CHIP | 1.89 (1.40–2.55) | P < 0.001 | |
| Large spliceosome CHIPSF3B1/SRSF2/U2AF1 | 3.02 (1.95–4.70) | P < 0.001 | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. Published 23 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →